USPTO serial 79278237
ROVIPIA
Reviewed by CopyMark Law Group
Reg. 6138770Status 404
- Filing date
- Status date
- Registration date
- Sep 1, 2020
- Examiner
- CORNWELL, ANDREA B
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ROVIPIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maury M. Tepper, III
Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRRALEIGH, NC 27609UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma; biological preparations for the treatment of bacterial infections, viral infections, inflammatory disorders, fungal infections, cardiovascular diseases and disorders, dermatological conditions, respiratory diseases and disorders, central nervous system diseases and disorders, gastrointestinal diseases and disorders, kidney diseases, diabetes, hypertension, skin disorders, cancer and tumors, allergies, bone diseases, diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the Musculo-skeletal system and the genitourinary system; biological preparations for use in hematology and in tissue and organ transplantation; biological preparations for prevention and treatment of eye diseases and conditions; biological preparations for the prevention and treatment of heart rhythm disorders; biological preparations for the prevention and treatment of immune system related diseases and disorders and stem cells for pharmaceutical and medical use | SECTION 70 - CANCELLED | — |
| 044 | Collection and preservation of blood; collection and preservation services for tissue and cells, namely, collection and banking of umbilical cord tissue perivascular stem cells; medical diagnostic services; medical treatment services; provision of medical information and data for diagnosis and medical treatment | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 3, 2026 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Sep 3, 2026 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Sep 1, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jan 23, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 31, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 31, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 1, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 1, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 16, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 16, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 27, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 7, 2020 | ALIE | ASSIGNED TO LIE | — |
| Apr 29, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 24, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 23, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 23, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 10, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 18, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 18, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 18, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 18, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 18, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 18, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 18, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 18, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 28, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 27, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 27, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 18, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 12, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 11, 2020 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Feb 6, 2020 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |